Nuformix finds positive data for NXP002 in lung fibrosis study
(Alliance News) - Nuformix PLC on Wednesday said fresh analysis of lung tissue from patients with idiopathic pulmonary fibrosis and autoimmune-related interstitial lung disease showed "positive" results for its lead asset NXP002, supporting its potential in treating a wider range of fibrotic conditions. Read More